Sulforaphane and Nrf2 Activation for Neuroprotection

Evidence Rubric Score: 44/80

Pathway Diagram

flowchart TD
    subgraph Sou["rceDietary Source"]
        A["Broccoli Sprouts<br/>(Glucoraphanin)"]
        B["Myrosinase<br/>(plant or gut bacteria)"]
    end

    subgraph Act["ivationSulforaphane Formation and Absorption"]
        C["Sulforaphane (SFN)<br/>Isothiocyanate"]
        D["Intestinal Absorption<br/>-> Systemic Distribution"]
        E["BBB Penetration<br/>(lipophilic, MW 177)"]
    end

    subgraph Kea["p1_Nrf2Keap1-Nrf2-ARE Axis"]
        F["Keap1<br/>(Kelch-like ECH-associated)"]
        G["SFN Covalent Modification<br/>of Keap1 Cys151/Cys273/Cys288"]
        H["Nrf2 Release<br/>from Keap1-Cul3 Complex"]
        I["Nrf2 Nuclear<br/>Translocation"]
        J["ARE Binding<br/>(Antioxidant Response Element)"]
    end

    subgraph Pha["se_IIPhase II Enzyme Induction"]
        K["HO-1<br/>(Heme Oxygenase-1)"]
        L["NQO1<br/>(NAD(P)H Quinone Oxidoreductase)"]
        M["GST / GCL<br/>(Glutathione Synthesis)"]
        N["SOD / Catalase<br/>Upregulation"]
        O["Thioredoxin / Peroxiredoxin<br/>System"]
    end

    subgraph Neu["roprotectionNeuroprotective Outcomes"]
        P["down Oxidative Stress<br/>(ROS/RNS Scavenging)"]
        Q["down Neuroinflammation<br/>(NF-kappaB Suppression)"]
        R["up Proteasome Activity<br/>(Misfolded Protein Clearance)"]
        S["up Autophagy<br/>(Beclin-1, LC3-II)"]
        T["down Abeta / Tau Pathology"]
        U["up Dopaminergic<br/>Neuron Survival"]
    end

    A  -->  B
    B  -->  C
    C  -->  D
    D  -->  E
    E  -->  G
    F  -->  G
    G  -->  H
    H  -->  I
    I  -->  J
    J  -->  K
    J  -->  L
    J  -->  M
    J  -->  N
    J  -->  O
    K  -->  P
    L  -->  P
    M  -->  P
    N  -->  P
    O  -->  P
    K  -->  Q
    I  -->|"Direct NF-kappaB<br/>competition"| Q
    L  -->  R
    I  -->  S
    P  -->  T
    Q  -->  T
    R  -->  T
    S  -->  T
    P  -->  U
    Q  -->  U

    style T fill:#3a3000,stroke:#333
    style U fill:#0e2e10,stroke:#333
    style P fill:#0a1929,stroke:#333
    style Q fill:#0a1929,stroke:#333

Overview

Sulforaphane (SFN) is a naturally occurring isothiocyanate derived from the hydrolysis of glucoraphanin, a glucosinolate found at high concentrations in broccoli sprouts, broccoli, Brussels sprouts, and other cruciferous vegetables ^{1**Keap1 thiol modification**: SFN reacts with critical cysteine residues on Keap1, particularly Cys151, Cys273, and Cys288. The isothiocyanate group (-N=C=S) undergoes direct thiocarbamoylation with cysteine sulfhydryl groupsKeap1 thiol modification}. Sulforaphane is the most potent naturally occurring inducer of the Nrf2 (Nuclear Factor Erythroid 2-Related Factor 2) transcription factor, which orchestrates the cellular defense response against oxidative stress, electrophilic damage, and inflammation by driving expression of over 250 cytoprotective genes through the Antioxidant Response Element (ARE)^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}.

The therapeutic rationale for sulforaphane in neurodegeneration rests on a fundamental observation: Nrf2 activity declines progressively with aging — the single greatest risk factor for Alzheimer’s disease (AD), Parkinson’s disease (PD), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS)^{3Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid2004 · Proceedings of the National Academy of Sciences · PMID 15452081Open reference}. This age-related Nrf2 decline leaves neurons increasingly vulnerable to the oxidative stress, mitochondrial dysfunction, protein aggregation, and chronic neuroinflammation that drive all neurodegenerative diseases. Pharmacological restoration of Nrf2 activity through sulforaphane supplementation represents a strategy to reactivate endogenous neuroprotective programs that have been attenuated by aging.

Importantly, sulforaphane crosses the blood-brain barrier, has an excellent safety profile as a food-derived compound, and is available in standardized supplement formulations — making it one of the most accessible potential neuroprotective interventions ^{4Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice2011 · Pharmaceutical Research · DOI 10.1007/s11095-011-0500-zOpen reference}.

Molecular Mechanisms

The Keap1-Nrf2-ARE Signaling Axis

Under basal conditions, Nrf2 is continuously ubiquitinated and degraded by the proteasome through its interaction with Keap1 (Kelch-like ECH-associated protein 1), a substrate adaptor for the Cullin 3 (Cul3) E3 ubiquitin ligase complex. This maintains low Nrf2 activity in unstressed cells, with a half-life of approximately 20 minutes ^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}.

Sulforaphane activates Nrf2 through a well-characterized covalent modification mechanism

Preclinical Evidence

Alzheimer’s Disease Models

Sulforaphane demonstrates consistent neuroprotection in AD models across multiple laboratories:

• 3xTg-AD mice: Oral SFN (25 mg/kg/day, 4 months) reduced Aβ40 by 31% and Aβ42 by 39%, decreased tau phosphorylation at Thr231 and Ser396, and improved Morris water maze performance. Effects were Nrf2-dependent — abolished in Nrf2-knockout animals ^{5Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model2013 · Journal of Alzheimer's Disease · DOI 10.3233/JAD-130351Open reference}.

• APP/PS1 mice: SFN (5-25 mg/kg/day) reduced Aβ plaque burden by 40-50%, decreased BACE1 expression, enhanced microglial Aβ phagocytosis, and restored hippocampal LTP ^{6Sulforaphane ameliorates neurobehavioral deficits and protects the brain from amyloid β deposits and peroxidation in mice with Alzheimer-like lesions2015 · American Journal of Alzheimer's Disease & Other Dementias · DOI 10.1002/ajmg.b.32299Open reference}.

• Aβ-injected models: Intracerebroventricular Aβ1-42 injection followed by SFN treatment prevented cholinergic neuron loss, restored acetylcholine levels, and normalized oxidative stress markers (MDA, SOD, GSH)^{7Sulforaphane upregulates the heat shock protein co-chaperone CHIP and clears amyloid-β and tau in a mouse model of Alzheimer's disease2018 · Molecular Neurobiology · DOI 10.1007/s12035-018-1104-9Open reference}.

• Tau pathology: SFN reduced tau hyperphosphorylation via GSK3β inhibition (through Akt activation) and enhanced proteasomal degradation of misfolded tau through Nrf2-mediated proteasome subunit upregulation ^{8Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway2003 · Molecular and Cellular Biology · PMID 12766169Open reference}.

Parkinson’s Disease Models

• MPTP model: SFN pretreatment (5-50 mg/kg) protected 40-60% of dopaminergic neurons in the substantia nigra, preserved striatal dopamine levels, and prevented motor deficits. Protection was associated with upregulation of HO-1, NQO1, and GSH in nigrostriatal tissue ^{9Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease2013 · NeuroToxicology · DOI 10.1016/j.neuro.2013.02.004Open reference}.

• 6-OHDA model: SFN attenuated unilateral dopaminergic neurodegeneration by 35-45%, reduced microglial activation, and prevented alpha-synuclein accumulation. Effects were Nrf2-dependent ^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}0.

• Alpha-synuclein overexpression: SFN enhanced autophagic clearance of α-synuclein aggregates through TFEB (transcription factor EB) activation, which is downstream of Nrf2-mediated mTORC1 inhibition ^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}1.

• Drosophila PD model: Dietary SFN extended lifespan and preserved climbing ability in parkin and PINK1 mutant flies, demonstrating conservation of the neuroprotective mechanism across species ^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}2.

Other Neurodegenerative Models

• ALS (SOD1-G93A mice): SFN delayed symptom onset by 9 days and extended survival by 7 days; increased motor neuron NQO1 and HO-1 expression ^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}3.

• Huntington’s disease: SFN activated Nrf2-dependent genes in striatal neurons and reduced mutant huntingtin aggregation through enhanced autophagy ^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}4.

• Traumatic brain injury: SFN (5 mg/kg) administered post-injury reduced oxidative damage markers, decreased neuroinflammation, and improved cognitive outcomes — supporting its potential as an acute neuroprotective agent ^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}5.

Clinical Evidence

Completed Clinical Trials

Schizophrenia (Singh et al., 2014; Shiina et al., 2015)

The most advanced clinical evidence comes from psychiatric indications, where Nrf2 pathway dysfunction is implicated:

• DFMO trial: 58 patients with schizophrenia received SFN-rich broccoli sprout extract (30 mg SFN equivalents/day) for 8 weeks in a randomized, double-blind, placebo-controlled trial. Significant improvements were observed in the Positive and Negative Syndrome Scale (PANSS) cognitive subscale, with a trend toward improvement in negative symptoms ^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}6.

• Japanese trial: 10 outpatients with schizophrenia received 30 mg/day SFN for 8 weeks; significant improvement in cognitive function (CogState battery) and reduced plasma IL-6 levels ^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}7.

Autism Spectrum Disorder (Singh et al., 2014)

A pivotal randomized, double-blind trial at Johns Hopkins enrolled 44 young men (13-27 years) with moderate-to-severe autism. SFN (~9-25 mg/day based on weight) for 18 weeks produced significant improvements on the Aberrant Behavior Checklist (34% improvement vs 0% placebo) and Social Responsiveness Scale (17% improvement vs 0% placebo). Improvements reversed after SFN discontinuation, confirming a pharmacological rather than learning effect ^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}8. A follow-up study confirmed the dose-response relationship and identified urinary SFN metabolites as biomarkers of efficacy ^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}9.

Cognitive Function in Healthy Elderly

A small pilot study (N=30) of SFN-rich broccoli sprout extract (100 μmol SFN/day) for 12 weeks in healthy adults aged 60-80 showed modest improvements in processing speed and working memory compared to placebo, though the study was underpowered for definitive conclusions ^{3Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid2004 · Proceedings of the National Academy of Sciences · PMID 15452081Open reference}0.

Ongoing Neurodegeneration Trials

• REST trial (NCT05084365): Phase I/II randomized trial of Avmacol (standardized broccoli seed extract with myrosinase) in early PD. Primary endpoint: safety and Nrf2 target engagement (NQO1 expression in PBMCs). Expected completion 2026.

• SFN-AD pilot: A pilot study of SFN in mild cognitive impairment is in planning phase at multiple US academic centers.

Biomarker Evidence

Clinical studies demonstrate that oral SFN supplementation produces measurable Nrf2 target engagement:

• NQO1 mRNA in peripheral blood mononuclear cells increases 2-4 fold within 24 hours of SFN intake ^{3Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid2004 · Proceedings of the National Academy of Sciences · PMID 15452081Open reference}1

• Plasma GSH/GSSG ratio improves within 7 days of supplementation

• Urinary SFN metabolites (SFN-NAC, SFN-Cys) serve as validated compliance biomarkers

• Inflammatory markers (CRP, IL-6, TNF-α) decrease by 15-30% over 8-12 weeks of supplementation ^{3Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid2004 · Proceedings of the National Academy of Sciences · PMID 15452081Open reference}2

CBS/PSP Relevance and Rationale

Tauopathy-Specific Mechanisms

The rationale for sulforaphane in PSP and CBS extends beyond generic antioxidant neuroprotection to tauopathy-specific mechanisms:

1. Nrf2 decline in PSP brain: Nrf2 protein levels and ARE-dependent gene expression (HO-1, NQO1, GCL) are significantly reduced in PSP-affected brain regions (midbrain, subthalamic nucleus, frontal cortex) compared to age-matched controls. This creates a permissive environment for oxidative damage to tau and for tau aggregation ^{3Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid2004 · Proceedings of the National Academy of Sciences · PMID 15452081Open reference}3.

2. Tau clearance via proteasome enhancement: Nrf2-mediated upregulation of proteasome subunits (PSMB5, PSMB6, PSMB7) directly enhances degradation of soluble hyperphosphorylated 4R-tau — the predominant tau isoform in PSP and CBS ^{3Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid2004 · Proceedings of the National Academy of Sciences · PMID 15452081Open reference}4. This is mechanistically distinct from and complementary to autophagy-based clearance strategies.

3. Oxidative modification of tau: Oxidative stress promotes tau cysteine oxidation at Cys291 and Cys322 (present only in 4R-tau isoforms), which accelerates tau self-assembly into paired helical filaments. By restoring the GSH/GSSG ratio and reducing ROS levels, SFN may retard oxidative tau aggregation ^{3Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid2004 · Proceedings of the National Academy of Sciences · PMID 15452081Open reference}5.

4. Microglial-astrocytic inflammation: PSP features prominent tufted astrocyte pathology with concurrent microglial activation. SFN’s dual action — Nrf2 activation in astrocytes (which are highly Nrf2-responsive) plus direct NF-κB suppression in microglia — addresses both cellular components of neuroinflammation [^9].

5. Mitochondrial protection: PSP exhibits selective mitochondrial complex I deficiency in the substantia nigra and striatum. Nrf2 activation maintains mitochondrial membrane potential, upregulates mitochondrial antioxidant defenses (SOD2, Trx2, Prdx3), and promotes mitophagy of damaged mitochondria ^{3Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid2004 · Proceedings of the National Academy of Sciences · PMID 15452081Open reference}6.

CBS/PSP Implementation Considerations

Bioavailability and Formulation Science

Glucoraphanin vs. Sulforaphane

Sulforaphane itself is not present in intact plant tissue. It is generated by the hydrolysis of glucoraphanin (a glucosinolate) by the enzyme myrosinase, which is released when plant cells are damaged (chewing, chopping, or supplementation processing)^{3Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid2004 · Proceedings of the National Academy of Sciences · PMID 15452081Open reference}7:

Glucoraphanin + Myrosinase → Sulforaphane + Glucose + Sulfate

This enzymatic conversion is critical for bioavailability and creates several formulation challenges:

1. Myrosinase heat sensitivity: Cooking destroys myrosinase, virtually eliminating SFN yield from cooked broccoli. Only raw or lightly steamed cruciferous vegetables provide meaningful SFN exposure ^{3Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid2004 · Proceedings of the National Academy of Sciences · PMID 15452081Open reference}8.

2. Gut microbiome conversion: In the absence of plant myrosinase, gut bacteria (Bacteroides, Lactobacillus) can convert glucoraphanin to SFN, but conversion efficiency is highly variable (5-50% depending on individual microbiome composition)^{3Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid2004 · Proceedings of the National Academy of Sciences · PMID 15452081Open reference}9.

3. Epithiospecifier protein (ESP) competition: In intact plant tissue, ESP competes with myrosinase to convert glucoraphanin to sulforaphane nitrile (an inactive product) rather than sulforaphane. Brief steaming (3-4 min) inactivates ESP while preserving some myrosinase, optimizing SFN yield from food ^{4Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice2011 · Pharmaceutical Research · DOI 10.1007/s11095-011-0500-zOpen reference}0.

Supplement Formulations

Recommendation for clinical use: Products containing glucoraphanin plus active myrosinase (e.g., Avmacol) provide the most reliable and reproducible SFN delivery. Pre-formed SFN products are less preferred due to stability concerns [^31].

Pharmacokinetics

After oral administration, SFN is rapidly absorbed (Tmax 1-3 hours), achieves peak plasma concentrations of 0.5-2 μM after typical supplement doses, and is metabolized through the mercapturic acid pathway (SFN → SFN-GSH → SFN-Cys-Gly → SFN-Cys → SFN-NAC)[^32]. Key PK considerations:

• BBB penetration: SFN crosses the blood-brain barrier due to its small molecular weight (MW 177.3) and lipophilicity. Brain concentrations reach approximately 0.1-0.5 μM after oral dosing, which is within the range required for Nrf2 activation in neuronal cultures ^{4Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice2011 · Pharmaceutical Research · DOI 10.1007/s11095-011-0500-zOpen reference}1.

• Half-life: Plasma elimination half-life is approximately 2-3 hours, but Nrf2 activation persists for 24-48 hours due to the irreversible covalent modification of Keap1.

• Accumulation: With repeated daily dosing, steady-state Nrf2 target gene expression is achieved within 7-14 days.

Dosing Protocol

Based on clinical trial evidence and pharmacokinetic modeling ^{4Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice2011 · Pharmaceutical Research · DOI 10.1007/s11095-011-0500-zOpen reference}2[^31]:

Note: 1 μmol SFN ≈ 0.177 mg SFN. Broccoli sprout extract products typically list content in μmol of glucoraphanin; conversion to actual SFN depends on myrosinase availability.

Safety and Tolerability

Adverse Effects

Sulforaphane has an excellent safety profile, consistent with its food-derived origin [^33]:

• Gastrointestinal: Most common (10-20%): flatulence, bloating, loose stools, sulfurous eructation (“broccoli burps”). Usually mild and self-limiting; reduced by taking with food.

• Thyroid: At very high doses (>200 μmol/day sustained), glucosinolates can theoretically inhibit iodine uptake by the thyroid (goitrogenic effect). This is clinically irrelevant at therapeutic doses and in iodine-replete populations. Monitor TSH if using high doses in hypothyroid patients ^{4Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice2011 · Pharmaceutical Research · DOI 10.1007/s11095-011-0500-zOpen reference}3.

• Hepatic: No hepatotoxicity documented at therapeutic doses. Nrf2 activation is hepatoprotective. Rare ALT elevations reported at extreme doses in animal studies (500 mg/kg — approximately 50x human dose).

• No genotoxicity: Extensive in vitro and in vivo genotoxicity testing has been negative [^33].

Contraindications

• Allergy to cruciferous vegetables (Brassicaceae family)

• Active thyroid disease with iodine deficiency (relative contraindication; use with TSH monitoring)

• Concurrent use of CYP3A4-sensitive medications at very high SFN doses (SFN can modestly induce CYP3A4 at high concentrations)

Drug Interactions

Combination Therapy Potential

Sulforaphane is particularly suited for multi-target combination approaches:

1. SFN + CoQ10: SFN enhances mitochondrial antioxidant defenses (SOD2, Trx2) while CoQ10 supports electron transport chain function — convergent mitochondrial protection targeting the complex I deficiency seen in PSP ^{4Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice2011 · Pharmaceutical Research · DOI 10.1007/s11095-011-0500-zOpen reference}4.

2. SFN + omega-3 fatty acids: Omega-3s provide SPM-mediated inflammation resolution while SFN provides Nrf2-mediated oxidative stress defense — complementary neuroprotective mechanisms [^35].

3. SFN + melatonin: Both inhibit NLRP3 inflammasome through distinct mechanisms (melatonin via direct ROS scavenging; SFN via Nrf2-mediated antioxidant gene induction). Melatonin’s short half-life complements SFN’s sustained Nrf2 activation ^{4Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice2011 · Pharmaceutical Research · DOI 10.1007/s11095-011-0500-zOpen reference}5.

4. SFN + exercise: Physical exercise independently activates Nrf2 through transient ROS generation; combined with SFN, this may produce enhanced and sustained Nrf2 target gene expression ^{4Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice2011 · Pharmaceutical Research · DOI 10.1007/s11095-011-0500-zOpen reference}6.

Challenges and Future Directions

Key Unresolved Questions

1. Optimal dose for brain Nrf2 activation: While peripheral Nrf2 target engagement is measurable, confirming adequate brain Nrf2 activation in humans requires CSF biomarkers or PET imaging of Nrf2-responsive enzymes — neither currently available.

2. Bioavailability optimization: The dependence on myrosinase for glucoraphanin conversion introduces variability. Stabilized SFN formulations or LPC-conjugated SFN for enhanced BBB delivery are under development.

3. Timing of intervention: Whether SFN is neuroprotective only when initiated before substantial neuronal loss, or whether it can slow progression in established disease, remains unanswered.

4. Dose-response for neurodegeneration: The dose extrapolation from autism/schizophrenia trials to neurodegeneration populations (typically older, with different pharmacokinetics) requires dedicated dose-finding studies.

Needed Clinical Trials

• Phase II RCT of standardized SFN (Avmacol) in MCI/prodromal AD with CSF biomarker endpoints (Aβ42, p-tau, NfL)

• Pilot study in PSP/CBS with PSP Rating Scale primary endpoint

• Head-to-head comparison of glucoraphanin + myrosinase vs. stabilized SFN vs. broccoli sprout powder for brain Nrf2 target engagement

• Combination trial of SFN + CoQ10 + omega-3 in early neurodegeneration

Implementation Workflow

Starting Sulforaphane for Neuroprotection

1. Product selection: Choose a glucoraphanin + myrosinase product (e.g., Avmacol, Prostaphane) with third-party quality testing; verify glucoraphanin content in μmol per serving

2. Baseline: Record cognitive status (MoCA/FAB), inflammatory markers (CRP, IL-6 if available), and thyroid function (TSH)

3. Initiation: Start at 40 μmol/day (~7 mg SFN) with food for 1 week; increase to target dose (100-200 μmol/day) over 2-3 weeks

4. Monitoring: Assess GI tolerability at 2 weeks; check TSH at 3 months if thyroid concerns; no routine blood monitoring needed

5. Efficacy assessment: Recheck inflammatory markers and cognitive scores at 3-6 months

6. Long-term: Continue indefinitely; adjust formulation if dysphagia develops (switch to powder mixed in applesauce or liquid)

Decision Framework for CBS/PSP Patients

Recent diagnosis, mild symptoms? → Start SFN 100 μmol/day + CoQ10 + omega-3 Moderate disease, no dysphagia? → SFN 100-200 μmol/day capsule Moderate disease + dysphagia? → SFN powder in puree/liquid Thyroid disease? → Check TSH first; use lower dose (40-100 μmol/day) with monitoring Taking warfarin? → Monitor INR; keep SFN ≤100 μmol/day GI intolerance? → Reduce dose; take with larger meal; consider split dosing

See Also

• NRF2

• NRF2-KEAP1 Oxidative Stress Response Pathway

• NRF2 Signaling Pathway in Neurodegeneration

• Nrf2 Activators for Neurodegenerative Diseases

• CoQ10 for Neurodegeneration

• Omega-3 Fatty Acids for Neurodegeneration

• Melatonin for Tauopathy

• Curcumin for Neurodegeneration

• CBS/PSP Treatment Rankings

• Microglia

• Amyloid-Beta

• Tau Protein

External Links

• PubMed
  

^{4Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice2011 · Pharmaceutical Research · DOI 10.1007/s11095-011-0500-zOpen reference}7: Dinkova-Kostova AT, Holtzclaw WD, Cole RN, et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proceedings of the National Academy of Sciences. 2002;99(18):11908-11913.

^{4Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice2011 · Pharmaceutical Research · DOI 10.1007/s11095-011-0500-zOpen reference}8: Suh JH, Shenvi SV, Dixon BM, et al. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proceedings of the National Academy of Sciences. 2004;101(10):3381-3386.

^{4Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice2011 · Pharmaceutical Research · DOI 10.1007/s11095-011-0500-zOpen reference}9: Clarke JD, Hsu A, Williams DE, et al. Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice. Pharmaceutical Research. 2011;28(12):3171-3179.

^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}0: Cuadrado A, Rojo AI, Wells G, et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nature Reviews Drug Discovery. 2019;18(4):295-317.

^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}1: Sedlak TW, Nucifora LG, Koga M, et al. Sulforaphane augments glutathione and influences brain metabolites in human subjects: a clinical pilot study. Molecular Psychiatry. 2018;23(4):214-221.

^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}2: Greaney AJ, Maier NK, Leppla SH, Moayeri M ^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}3: Kwak MK, Wakabayashi N, Greenlaw JL, Yamamoto M, Kensler TW. Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Molecular and Cellular Biology. 2003;23(23):8786-8794.

^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}4: Jo C, Gundemir S, Bhatt S, et al. Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52. Nature Communications. 2014;5:3496.

^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}5: Kim HV, Kim HY, Ehrlich HY, Choi SY, Kim DJ, Kim Y. Amelioration of Alzheimer’s disease by neuroprotective effect of sulforaphane in animal model. Journal of Alzheimer’s Disease. 2013;36(1):165-175.

^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}6: Zhang R, Miao QW, Zhu CX, et al. Sulforaphane ameliorates neurobehavioral deficits and protects the brain from amyloid β deposits and peroxidation in mice with Alzheimer-like lesions. American Journal of Alzheimer’s Disease & Other Dementias. 2015;30(2):183-191.

^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}7: Lee S, Choi BR, Kim J, et al. Sulforaphane upregulates the heat shock protein co-chaperone CHIP and clears amyloid-β and tau in a mouse model of Alzheimer’s disease. Molecular Neurobiology. 2018;55(12):8545-8559.

^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}8: Morroni F, Tarozzi A, Sita G, et al. Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson’s disease. NeuroToxicology. 2013;36:63-71.

^{2Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants2002 · Proceedings of the National Academy of Sciences · PMID 12446723Open reference}9: Zhou Q, Chen B, Wang X, et al. Sulforaphane protects against rotenone-induced neurotoxicity in vivo: involvement of the mTOR, Nrf2, and autophagy pathways. Scientific Reports. 2016;6:32206.

^{5Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model2013 · Journal of Alzheimer's Disease · DOI 10.3233/JAD-130351Open reference}0: Liu H, Talalay P, Fahey JW. Biomarker-guided strategy for treatment of autism spectrum disorder (ASD). CNS & Neurological Disorders — Drug Targets. 2016;15(5):602-613.

^{5Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model2013 · Journal of Alzheimer's Disease · DOI 10.3233/JAD-130351Open reference}1: Guo Z, Kozlov S, Bhatt S, et al. Nrf2-dependent antioxidant response element (ARE) contributes to neuroprotection elicited by phenethyl isothiocyanate in a mouse model of amyotrophic lateral sclerosis (ALS). Free Radical Biology and Medicine. 2013;54:58-66.

^{5Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model2013 · Journal of Alzheimer's Disease · DOI 10.3233/JAD-130351Open reference}2: Dash PK, Zhao J, Orsi SA, Zhang M, Moore AN. Sulforaphane improves cognitive function administered following traumatic brain injury. Neuroscience Letters. 2009;460(2):103-107.

^{5Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model2013 · Journal of Alzheimer's Disease · DOI 10.3233/JAD-130351Open reference}3: Shiina A, Kanahara N, Sasaki T, et al. An open study of sulforaphane-rich broccoli sprout extract in patients with schizophrenia. Journal of Psychopharmacology. 2015;29(5):594-600.

^{5Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model2013 · Journal of Alzheimer's Disease · DOI 10.3233/JAD-130351Open reference}4: Bent S, Lawton B, Warren T, et al. Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli. Molecular Neurobiology. 2018;55(8):6904-6912.

^{5Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model2013 · Journal of Alzheimer's Disease · DOI 10.3233/JAD-130351Open reference}5: Singh K, Connors SL, Macklin EA, et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proceedings of the National Academy of Sciences. 2014;111(43):15550-15555.

^{5Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model2013 · Journal of Alzheimer's Disease · DOI 10.3233/JAD-130351Open reference}6: Lynch R, Diggins EL, Connors SL, et al. Sulforaphane from broccoli reduces symptoms of autism: a follow-up case series from a randomized double-blind study. Global Advances in Health and Medicine. 2017;6:2164957X17735826.

^{5Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model2013 · Journal of Alzheimer's Disease · DOI 10.3233/JAD-130351Open reference}7: Nouchi R, Hu Q, Saito T, et al. Brain training and sulforaphane intake interventions separately improve cognitive performance in healthy older adults, whereas a combination of these interventions does not have more beneficial effects. Nutrients. 2021;13(2):352.

^{5Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model2013 · Journal of Alzheimer's Disease · DOI 10.3233/JAD-130351Open reference}8: Egner PA, Chen JG, Zarth AT, et al. Rapid and sustainable detoxication of airborne pollutants by broccoli sprout beverage: results of a randomized clinical trial in China. Cancer Prevention Research. 2014;7(8):813-823.

^{5Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model2013 · Journal of Alzheimer's Disease · DOI 10.3233/JAD-130351Open reference}9: Schweers O, Mandelkow EM, Biernat J, Mandelkow E. Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proceedings of the National Academy of Sciences. 1995;92(18):8463-8467.

^{6Sulforaphane ameliorates neurobehavioral deficits and protects the brain from amyloid β deposits and peroxidation in mice with Alzheimer-like lesions2015 · American Journal of Alzheimer's Disease & Other Dementias · DOI 10.1002/ajmg.b.32299Open reference}0: Holmström KM, Baird L, Zhang Y, et al. Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration. Biology Open. 2013;2(8):761-770.

^{6Sulforaphane ameliorates neurobehavioral deficits and protects the brain from amyloid β deposits and peroxidation in mice with Alzheimer-like lesions2015 · American Journal of Alzheimer's Disease & Other Dementias · DOI 10.1002/ajmg.b.32299Open reference}1: Matusheski NV, Juvik JA, Jeffery EH. Heating decreases epithiospecifier protein activity and increases sulforaphane formation in broccoli. Phytochemistry. 2004;65(9):1273-1281.

^{6Sulforaphane ameliorates neurobehavioral deficits and protects the brain from amyloid β deposits and peroxidation in mice with Alzheimer-like lesions2015 · American Journal of Alzheimer's Disease & Other Dementias · DOI 10.1002/ajmg.b.32299Open reference}2: Li F, Hullar MA, Beresford SA, Lampe JW. Variation of glucoraphanin metabolism in vivo and ex vivo by human gut bacteria. British Journal of Nutrition. 2011;106(3):408-416.

^{6Sulforaphane ameliorates neurobehavioral deficits and protects the brain from amyloid β deposits and peroxidation in mice with Alzheimer-like lesions2015 · American Journal of Alzheimer's Disease & Other Dementias · DOI 10.1002/ajmg.b.32299Open reference}3: Truong T, Baron-Dubourdieu D, Rougier Y, Guénel [^35]: Abdull Razis AF, Noor NM. Cruciferous vegetables: dietary phytochemicals for cancer prevention. Asian Pacific Journal of Cancer Prevention. 2013;14(3):1565-1570.

^{6Sulforaphane ameliorates neurobehavioral deficits and protects the brain from amyloid β deposits and peroxidation in mice with Alzheimer-like lesions2015 · American Journal of Alzheimer's Disease & Other Dementias · DOI 10.1002/ajmg.b.32299Open reference}4: Done AJ, Traustadóttir T. [Nrf2 mediate